SynthesisBJU international2025
Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals.
Synthesis in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prostate specific antigen retesting intervals and trends in England: population based cohort study.BMJ (Clinical research ed.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo summarise the recommendations for prostate-specific antigen (PSA) retesting intervals and to evaluate the evidence cited by each guideline by conducting a systematic review of clinical practice guidelines.
methodsWe searched PubMed and the Turning Research into Practice (TRIP) database for guidelines written in English and developed or updated in 2013-2024. Guideline quality assessment was performed using the AGREE II tool. We narratively synthesised results.
resultsEleven guidelines were included. Ten (91%) recommended PSA retesting intervals of approximately 2 to 4 years. A total of 37 studies were referenced as evidence for the recommended intervals across the 11 guidelines. Five of these studies (14%) had the objective of determining PSA retesting intervals. Fourteen studies (38%) analysed single PSA test results. Five guideline recommendations partially aligned with the evidence referenced and five did not align.
conclusionsGenerally, for asymptomatic patients aged ≥50 years with PSA levels between 1 and 3 ng/mL, most guidance recommended a retesting interval of 2-4 years, with the possibility to extend the interval to 4-10 years for patients with a PSA value <1 ng/mL. Until research generates direct evidence for PSA retesting intervals for both asymptomatic and symptomatic patients, clinicians and patients engaging in shared decision-making should be aware that current guidelines lack direct evidence for recommended PSA retesting intervals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.